S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Price, News & Analysis

$5.85
-0.23 (-3.78%)
(As of 04/16/2024 ET)
Today's Range
$5.85
$6.03
50-Day Range
$6.08
$11.07
52-Week Range
$5.85
$11.91
Volume
1.34 million shs
Average Volume
1.82 million shs
Market Capitalization
$478.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
156.4% Upside
$15.00 Price Target
Short Interest
Bearish
20.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.52mentions of Editas Medicine in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$924,582 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.61) to ($2.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

277th out of 930 stocks

Biological Products, Except Diagnostic Industry

36th out of 150 stocks

EDIT stock logo

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

EDIT Stock News Headlines

BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
Q4 2023 Editas Medicine Inc Earnings Call
Here's what Wall Street expects from Editas Medicine's earnings report
Earnings Outlook For Editas Medicine
Editas Medicine Q4 2023 Earnings Preview
EDIT Mar 2024 7.000 put
EDIT Mar 2024 12.000 call
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
265
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+155.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-153,220,000.00
Net Margins
-196.12%
Pretax Margin
-196.12%

Debt

Sales & Book Value

Annual Sales
$78.12 million
Book Value
$4.27 per share

Miscellaneous

Free Float
80,014,000
Market Cap
$481.04 million
Optionable
Optionable
Beta
2.02
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Gilmore O'Neill M.D. (Age 59)
    President, CEO & Director
    Comp: $815.37k
  • Dr. Baisong Mei M.D.
    Ph.D., Senior VP & Chief Medical Officer
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 70)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Erick J. Lucera C.F.A. (Age 56)
    CPA, CFO & Executive VP
  • Dr. Linda C. Burkly Ph.D.
    Executive VP & Chief Scientific Officer
  • Cristi Barnett
    Corporate Communications & Investor Relations
  • Ms. Charlene Stern J.D.
    Ph.D., Executive VP & General Counsel

EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EDIT shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price target for 2024?

9 brokers have issued twelve-month target prices for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2024?

Editas Medicine's stock was trading at $10.13 on January 1st, 2024. Since then, EDIT shares have decreased by 42.3% and is now trading at $5.85.
View the best growth stocks for 2024 here
.

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 8.9 days.
View Editas Medicine's Short Interest
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Wednesday, February, 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.29. The company had revenue of $60 million for the quarter, compared to analysts' expectations of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. The company's revenue was up 817.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

Editas Medicine (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners